OPA Bulletin

  • News for the Week of September 29, 2020

    This content is only available to Association members. Please log in to access this content.

    Become a member

    or Sign In

    • Update on COVID-19 Testing in Pharmacies
    • Updated: COVID-19 Provincial Testing Guidance
    • Universal Influenza Immunization Program (UIIP) Updates
    • NIHB Program: Availability of US Labelled SUBLOCADE Product on Canadian Market Due to Shortage
    • Red Cross Recertification Extension

    • Secure Your Stock of Hand Sanitizer
    • Dell Canada Special Offer

    • *FREE* Training for Asymptomatic COVID-19 Testing in Pharmacy
    • *FREE* Protecting Your Patients: Operationalizing Adult Immunizations
    • Injections and Immunizations Certificate Program

    • Deadline to Get your 15% Reduced Driving Refund Extended
    • Protect your Family with OPA Group Health Plan

    • Week of September 21 – DSU Weekly Update to Provinces and Territories

    • DDD Notice No. 20148 Posted September 24, 2020: ODB Formulary Edition No. 43, Summary of Changes – September 30, 2020
    • DDD Notice No. 20147 Posted September 24, 2020 Prescription Forgery Alert
    • DDD Notice No. 20146 Posted September 23, 2020 Prescription Forgery Alert

    • Health Product InfoWatch, September 2020
    • All Strengths of Mar-Diltiazem CD, a Drug Used to Treat Angina and Hypertension, Have Been Recalled Because of Dosing Concerns
    • Recall of Certain Hand Sanitizers That May Pose Health Risks

  • News for the Week of September 22, 2020

    This content is only available to Association members. Please log in to access this content.

    Become a member

    or Sign In

    • Ontario Pharmacists Pleased to Play a Role in Ontario Government’s Fall Preparedness Plan
    • COVID-19 Testing and Regulatory Changes Update
    • M Postal Code Flu Vaccine Distribution
    • Updated: OPA’s Universal Influenza Immunization Program (UIIP) 2020-21 Frequently Asked Questions
    • Community Practice Environment Initiative - Registrant Survey

    • Ask the Customer Experience and Administration Team
    • The Ontario Pharmacist (TOP) Magazine Available Now!
    • Canadian Red Cross Reminder: Act Quickly! Register for Certification Courses Now

    • A Practical Approach to Laboratory Abnormalities
    • Managing Your Pharmacy: The Business Essentials
    • OPA’s Webinar Series: The Right Dose - Protecting Your Patients: Operationalizing Adult Immunizations

    • OPA Secure Health Plan Rate Changes
    • Student Travel Insurance Notice

    • Health Canada Reviews Safety of Drug Fibristal Again Following New Case of Liver Injury

  • News for the Week of September 15, 2020

    This content is only available to Association members. Please log in to access this content.

    Become a member

    or Sign In

    • Is COVID-19 Testing Coming to Pharmacies?
    • CPhA News Release: Canadians Urge Expanding COVID-19 Asymptomatic Testing Across Canada
    • ICYMI: Important Reminder Regarding Age-eligibilities for Pharmacist-administered Flu Vaccinations Under the UIIP 2020-2021
    • Suggested Best Practices for Community Pharmacy Providing Influenza Immunizations During the COVID-19 Pandemic
    • COVID-19 Resources and Tools
    • ICYMI: Students of OPA – Share Your Voice and Shape the Future of the Profession
    • Pharmacists' Matters: COVID-19 Testing in Pharmacy - The Alberta Story

    • Ask the Practice Support Network

    • How Can Pharmacists Optimize the Care of Patients With Heart Failure?
    • Pharmacist Health Coaching – Cardiovascular Program Training Course
    • Digital Disruption and Impending Changes - Ideas for Survival

    • Universal Influenza Immunization Program and OPA Store Insurance

    • Health Canada Drug Shortages Updates – Week of September 7, 2020

    • Important Safety Information on ESBRIET (pirfenidone) – Risk of Drug-Induced Liver Injury
    • Recall of Certain Hand Sanitizers That May Pose Health Risks
    • Importation of US Clinical Trial-Labelled Remdesivir for Injection Due to Shortage of Canadian-Labelled Remdesivir - Gilead Sciences Canada, Inc.

  • News for the Week of September 8, 2020

    This content is only available to Association members. Please log in to access this content.

    Become a member

    or Sign In

    • ICYMI: Changes to the 2020-21 Universal Influenza Immunization Program (UIIP)
    • OPA’s Universal Influenza Immunization Program (UIIP) 2020-21 Frequently Asked Questions
    • Guidance for Influenza Vaccine Delivery in the Presence of COVID-19
    • OPA Submission to Amendments to Regulations 682 and 683 under the Laboratory Specimen Collection Centre Licensing Act, 1990
    • OPA Submission to Proposed Regulations under the Connecting People to Home and Community Care Act, 2020
    • Controlled Drugs and Substances Act Section 56 Exemption Extension to September 30, 2021
    • COVID-19 Resources and Tools
    • Inaugural meeting of OPA's Diversity Task Force
    • External Research Initiatives and Resources

    • Ask Customer Experience Administration Team
    • Order PPE Faster, Easier and Save More!
    • Ripley's Aquarium Offers Discount for OPA Members
    • Prepare Your Store/Workplace for the Fall Season, Order Hand Sanitizers Today

    • Landmark Changes in Asthma Management
    • A Practical Approach to Laboratory Abnormalities
    • Pharmacist Health Coaching – Cardiovascular Program Training Course

    • Business Expense Disability Insurance

    • Health Canada Drug Shortages Updates, August 12, 2020
    • Health Canada Drug Shortages Updates, August 18, 2020
    • Health Canada Drug Shortages Updates – Week of August 24, 2020

    • DDD Notice 20129 Posted August 5, 2020 Executive Officer Notice: Funding of Allerject® (Epinephrine Auto-Injector) Through the Allergen Program
    • DDD Notice No. 20130 Posted August 5, 2020 Prescription Forgery Alert
    • DDD Notice No. 20132 Posted August 14, 2020: Notice from the EO – Monitored Drugs List (MDL) Update Effective: August 14, 2020
    • DDD Notice No. 20133 Posted August 21, 2020: ODB Formulary Edition No. 43, Summary of Changes – August 28, 2020
    • DDD Notice No. 20134 Posted August 24, 2020: Executive Officer Notice and Frequently Asked Questions: Funding of Riximyo and Ruxience Under the Ontario Drug Benefit Program
    • DDD Notice No. 20136 Posted August 28, 2020 Prescription Forgery Alert
    • DDD Notice No. 20137 Posted August 28, 2020 Prescription Forgery Alert
    • DDD Notice No. 20138 Posted September 3, 2020 Prescription Forgery Alert
    • DDD Notice No. 20139 Posted September 3, 2020 Prescription Forgery Alert
    • DDD Notice No. 20140 Posted September 4, 2020 Health Network System (HNS) and Narcotics Monitoring System (NMS) Outage Notification to Ontario Drug Programs Agencies

    • Recall of Certain Hand Sanitizers that Contain Technical-grade Ethanol
    • Prescription Cough and Cold Products Containing Opioids and the Risk of Opioid Use Disorder in Children and Adolescents (< 18 years of age)
    • Health Product InfoWatch, August 2020
    • UPDATE – Pharmascience Inc. Recalls One Lot of PMS-Ranitidine as a Precaution
    • Hand Sanitizers in Non-Traditional Packaging, Including Squeeze Pouches Commonly Used for Food and Beverages
    • Recall of Certain Hand Sanitizers That May Pose Health Risks

  • News for the Week of August 4, 2020

    This content is only available to Association members. Please log in to access this content.

    Become a member

    or Sign In

    • Preparing for Stage 3 and Flu Season
    • Encourage Your Patients to Download the COVID Alert App to Prevent Community Spread of COVID-19
    • COVID-19 Resources and Tools
    • External Research Initiatives and Resources

    • Ask the Practice Support Network

    • Complimentary Live Webinar: Landmark Changes in Asthma Management

    • Surviving a Critical Illness
    • Professional Liability Insurance Claims Reporting

    • Health Canada Drug Shortages Updates, July 29, 2020

    • DDD Notice No. 20128 posted August 4, 2020 Prescription Forgery Alert
    • DDD Notice No. 20127 posted August 4, 2020 Prescription Forgery Alert
    • DDD Notice No. 20124 posted July 30, 2020 Executive Officer Notice: Inspections Return to Work

    • Health Product InfoWatch, July 2020
    • Recall of Certain Hand Sanitizers That May Pose Health Risks
    • Non-Prescription Pain Relief Products Containing Codeine Are Not Recommended for Use in People Under 18 Years of Age

  • News for the Week of July 28, 2020

    This content is only available to Association members. Please log in to access this content.

    Become a member

    or Sign In

    • OPA Submission - Regulatory Amendments to Ontario Regulation 202/94 (General) made under the Pharmacy Act, 1991
    • OPA Submission – Proposed Regulatory Amendments to Ontario Regulation 329/04 under the Personal Health Information Protection Act, 2004
    • Pharmacy Audits by Third-party Payors on ODB Co-payments Submitted During the Ministry's COVID-19 Supply Limit Recommendation
    • Reminder: Express Scripts Canada (ESC) Claims Submissions over $9,999.99

    • Ask the Customer Experience and Administration Team

    • The MASTER Plan for Diabetes Continuing Education Program
    • Mastering Injections in Pediatrics
    • Providing LGBTQ+ Inclusive Care at Your Pharmacy

    • Hospital Coverage Is Provided by Your OPA Secure Health Plan
    • Pharmacy Risk Prevention Tips

    • DDD Notice No. 20123 Posted July 28, 2020 Prescription Forgery Alert
    • DDD Notice No. 20121 Posted July 24, 2020: Notice from the Executive Officer – Monitored Drugs List (MDL) Update Effective: July 24, 2020
    • DDD Notice No. 20120 Posted July 24, 2020: ODB Formulary Edition No. 43, Summary of Changes – July 31, 2020
    • DDD Notice No. 20119 Posted July 24, 2020 Prescription Forgery Alert

    • Status of Ranitidine Drugs in Canada
    • Remdesivir Authorized with Conditions for the Treatment of Patients in Canada with Severe COVID-19 Symptoms

  • News for the Week of July 21, 2020

    This content is only available to Association members. Please log in to access this content.

    Become a member

    or Sign In

    • Reminder: Public Consultation on the Regulatory Amendments for Expansion of Scope Closing July 27, 2020
    • Non-Insured Health Benefits (NIHB) Program Providers Update
    • Concerns, Beliefs and Attitudes of Pharmacists About Cannabis Use Survey
    • New Episode of Pharmacists' Matters Available Now

    • Ask the Practice Support Network
    • Reduced Pricing on Hand Sanitizer for Pharmacy Professionals

    • An Update on Direct Oral Anticoagulation
    • Managing Your Pharmacy: The Business Essentials
    • Board Certified Geriatric Pharmacist (BCGP) Preparation Course – Medication Therapy Management for Older Adults

    • Why Students Need Life Insurance
    • Dependent Children’s Insurance

    • Importation of PTU™ (Propylthiouracil) 50 mg due to Shortage of Canadian Labelled Propylthiouracil 50 mg Products

    • DDD Notice No. 20117 Posted July 21, 2020 Prescription Forgery Alert
    • DDD Notice No. 20116 Posted July 15, 2020 Prescription Forgery Alert

    • Three Lots of Antidiuretic DDAVP Spray Recalled Because of Potential Overdose Risk
    • Health Canada Important Safety Information on Methadone Treatment of Opioid Dependence and Potential Risk of Lack of Effect when Switching between Different Products

  • News for the Week of July 14, 2020

    This content is only available to Association members. Please log in to access this content.

    Become a member

    or Sign In

    • ODPRN Ontario Prescription Opioid Tool: Quarterly Update – COVID-19 Insights
    • Update from the Canadian Red Cross
    • TELUS Health 2020 Health Drug Data Trends and National Benchmarks Report
    • CPhA COVID-19 Resource: In-pharmacy Poster for Encouraging Use of Masks

    • Ask the Customer Experience and Administration Team

    • How to Add Value to the Pharmacy Business as a Pharmacy Technician
    • Applying NAPRA's Non-Sterile Compounding Standards Into Practice
    • Mastering Injections in Pediatrics

    • COSECO Insurance Company unites with Co-operators General Insurance Company
    • Do I Need Life insurance?

    • DDD Notice No. 20113 posted July 13, 2020 Prescription Forgery Alert
    • DDD Notice No. 20112 posted July 9, 2020 Prescription Forgery Alert

  • News for the Week of July 7, 2020

    This content is only available to Association members. Please log in to access this content.

    Become a member

    or Sign In

    • ICYMI: OPA Board Elections
    • FINAL REMINDER: UIIP Application Deadline is Friday, July 10
    • Updated: OPA’s COVID-19 Insurance Exceptions Tool
    • NIHB Program Launches New Claims Processing System and Services via Express Scripts Canada

    • Ask the Practice Support Network
    • Summer Benefit Reminders for OPA Members

    • Pandemic Tips: Return to Work Guidance
    • How Can Pharmacists Optimize the Care of Patients with Heart Failure?
    • The Right Dose: The Positives and Negatives of COVID-19 Testing in Pharmacies

    • Get Your 15% Reduced Driving Refund
    • Are You Insured Through Your Employer’s Group Plan for Long-Term Disability (LTD)?

    • Use of the Drug Picato May Increase the Risk of Skin Cancer
    • Recall of Certain Hand Sanitizers That May Pose Health Risks
    • Certain Vials of Fertility Drug Cetrotide Recalled Because of Potential Contamination
    • Counterfeit Respirators

  • News for the Week of June 30, 2020

    This content is only available to Association members. Please log in to access this content.

    Become a member

    or Sign In

    • ICYMI: Regulations Posted for Consultation to Allow Pharmacists to Perform Point-Of-Care Tests
    • Updated: COVID-19 Resources and Tools
    • Hand Sanitizers Available to Pharmacies for Resale to Public
    • UIIP Deadline of July 10 is Fast Approaching
    • Express Scripts Canada – Transition to New Claims Processing System
    • ICYMI: New Podcast Released - LGBTQ+ Care in Pharmacy

    • Ask the Customer Experience and Administration Team
    • OPA Conference 2020 Survey Draw Winners

    • Pandemic Tips: Opioid Agonist Therapy

    • OPA Professional Liability — Extended Reporting Period
    • OPA Store Insurance Renewal 2020 - 2021

    • DDD Notice No. 20109 Posted June 29, 2020 Prescription Forgery Alert
    • DDD Notice No. 20108 Posted June 26, 2020 Health Network System (HNS) and Narcotics Monitoring System (NMS) Outage Notification to Ontario Drug Programs Agencies
    • DDD Notice No. 20107 posted June 24, 2020 Introducing SADIE 2.0 – Now With Designates!

    • Recall of Certain Hand Sanitizers That May Pose Health Risks
    • Health Product InfoWatch – June 2020
    • Recall of Certain Hand Sanitizers That Contain Technical-Grade Ethanol
    • NARDIL (Phenelzine Sulfate) Shortage

  • News for the Week of June 23, 2020

    This content is only available to Association members. Please log in to access this content.

    Become a member

    or Sign In

    • ICYMI: Call for OPA Committee Members
    • New Podcast Episode Released: LGBTQ+ Care in Pharmacy
    • Updated: COVID-19 Resources and Tools
    • Patented Medicine Prices Review Board (PMPRB) Draft Guidelines Consultation
    • OPA's First Virtual Annual General Meeting and Open Forum

    • Ask the Practice Support Network
    • Reminder: Nominate a Candidate for the Bowl of Hygeia

    • Complimentary Live Webcast on June 24: The Positives and Negatives of COVID-19 Testing in Pharmacies
    • Online Program Registration Now Open: Providing LGBTQ+ Inclusive Care At Your Pharmacy
    • Pandemic Tips: Pharmacy Technician’s Role in Supporting Patients and Pharmacy During the Pandemic

    • Business Expense Disability Insurance

    • DDD Notice No. 20104 posted June 22, 2020 Prescription Forgery Alert
    • DDD Notice No. 20105 posted June 22, 2020: ODB Formulary Edition No. 43, Summary of Changes June 30, 2020
    • DDD Notice No. 20106 posted June 23, 2020 Prescription Forgery Alert

    • Health Canada Drug Shortages Updates, June 17, 2020
    • Health Canada Drug Shortages Updates, June 18, 2020

    • Recall of Certain Hand Sanitizers That May Pose Health Risks
    • Important Safety Information on MabCampath (alemtuzumab) – Risk of Haemophagocytic Lymphohistiocytosis, Stroke (including ischaemic and haemorrhagic stroke), and Glomerulonephritis - Sanofi-Aventis Canada Inc.

  • News for the Week of June 16, 2020

    This content is only available to Association members. Please log in to access this content.

    Become a member

    or Sign In

    • ICYMI: Regulatory Amendments for Expansion of Scope Posted for Public Consultation
    • ICYMI: Removal of the Ministry’s 30-days’ Supply Dispensing Limit Recommendation
    • ICYMI: Message From OPA's CEO: Our Commitment to Create a Diversity Task Force
    • Updated: COVID-19 Resources and Tools
    • Extension of Red Cross First-Aid Certification

    • All OPA Awards Except Bowl of Hygeia Moved to 2021
    • Ask the Customer Experience and Administration Team

    • Pandemic Tips: Leveraging Mobile Apps in Pharmacy During COVID-19

    • Is Protecting Your Family and Business a Priority?
    • ICYMI: Get Your Reduced Driving Refund

    • DDD Notice No. 20102 posted June 12, 2020 Executive Officer Notice: Removal of the 30-days' Supply Dispensing Limit Recommendation

    • Health Canada Drug Shortages Updates, June 15, 2020
    • Health Canada Drug Shortages Updates, June 16, 2020

    • Certain Metformin Diabetes Drugs Recalled Due to the Presence or Possible Presence of NDMA
    • Risk of Poisoning From Hand Sanitizers Sold in Beverage Containers

  • News for the Week of June 9, 2020

    This content is only available to Association members. Please log in to access this content.

    Become a member

    or Sign In

    • Pharmacist’s Role in Managing Opioid Use Disorder During COVID-19
    • External Research Initiatives and Resources

    • Ask the Practice Support Network
    • OPA’s Newest Member Benefit Partner, Relief Buddy
    • Complete OPA's Conference Survey for a Chance to Win a Prize

    • Pandemic Tips: Leveraging Mobile Apps in Pharmacy During COVID-19

    • Professional Liability Insurance Claims Reporting

    • DDD Notice No. 20100 Posted June 4, 2020 Prescription Forgery Alert

    • Recall of Certain Hand Sanitizers That May Pose Health Risks

  • News for the Week of June 2, 2020

    This content is only available to Association members. Please log in to access this content.

    Become a member

    or Sign In

    • OPA Guidance for the Provision of Pharmacy Services in Long-term Care During the COVID-19 Pandemic
    • Update on Providing MedsChecks During COVID-19
    • ICYMI: OPA AGM and Open Forum Reminder
    • Updated: OPA's COVID-19 Insurance Exceptions Tool
    • Pharmacists' Matters - Episode 4: OPA’s Member Engagement Initiatives During the Pandemic
    • Resources for Seniors and People with Disabilities through the Ontario Community Support Program
    • OPA's Statement Supporting Diversity and Inclusivity

    • Ask the Customer Experience and Administration Team

    • Pandemic Tips: Financial Resources for Pharmacies Part 2

    • OPA Term 10 Life Insurance Convertible Feature
    • OPA Store Renewal 2020-2021

    • DDD Notice No. 20099 posted June 2, 2020 Prescription Forgery Alert

    • Health Canada Advises Canadians to Help Support the Continued Supply of Medications
    • Health Product InfoWatch - May 2020
    • Consumers Advised to Stop Using Akwaton International Multipurpose Wipes
    • Some Units of Triton Hand Sanitizer Containing Technical-Grade Ethanol Sold in Canada Without the Necessary Risk Information

  • News for the Week of May 26, 2020

    This content is only available to Association members. Please log in to access this content.

    Become a member

    or Sign In

    • ICYMI: Universal Influenza Immunization Program (UIIP) Now Open for Applications
    • ICYMI: OPA Submission to OCP on Regulatory Amendments to Enable Minor Ailments Prescribing
    • Updated: COVID-19 Testing Direction and Reference Document for Symptoms
    • Updated: Chief Medical Officer of Health Directive #2
    • OPA Supplementary FAQs Addressing Executive Officer Notice: Funding of Teva UK-labelled PrSalamol CFC-Free (Salbutamol Sulfate) Inhaler as a Temporary Benefit on the Ontario Drug Benefit (ODB) Formulary
    • Updated TELUS Health Provider Agreement
    • Pharmacists' Matters - Episode 3: Pharmacy and Pandemic Resources

    • Manulife Advantage Account

    • Reminder: Session Three of the Methadone, Buprenorphine and the Community Complimentary Live Webinar Series
    • Pandemic Tips: Financial Resources for Pharmacies

    • Universal Influenza Immunization Program and OPA Store Insurance

    • DDD Notice No. 20097 Posted May 26, 2020 Prescription Forgery Alert
    • DDD Notice No. 20096 Posted May 26, 2020 Prescription Forgery Alert
    • DDD Notice No. 20095 Posted May 22, 2020: 2020/21 Universal Influenza Immunization Program Notice to Pharmacies
    • DDD Notice No. 20094 Posted May 21, 2020 Executive Officer Notice: Funding of Teva UK-labelled Salamol CFC-Free (Salbutamol Sulfate) Inhaler as a Temporary Benefit on the Ontario Drug Benefit (ODB) Formulary
    • DDD Notice No. 20093 Posted May 21, 2020 ODB Formulary Edition No. 43, Summary of Changes – May 29, 2020
    • DDD Notice No. 20092 Posted May 21, 2020 Prescription Forgery Alert

    • Cisatracurium Omega Multi-Dose (Cisatracurium Besylate Injection): Temporary Change of Ferrule (Metal Seal) Colour to Maintain Continued Supply in Canada - Omega Laboratories Limited
    • Importation of US-labelled Rocuronium Bromide Injection distributed by Avir Pharma Inc. Due to Shortage of Canadian-labelled Rocuronium
    • Importation of US-labelled Rocuronium Bromide Injection Due to Shortage of Canadian-labelled Rocuronium - SteriMax Inc.

  • News for the Week of May 19, 2020

    This content is only available to Association members. Please log in to access this content.

    Become a member

    or Sign In

    • OPA Welcomes Government Support in Managing 30-days' Supply Limits
    • OPA Supports Teva Canada in Mitigation of Salbutamol Shortages
    • Updated: COVID-19 Resources and Tool
    • Health Canada Toolkit: COVID-19 and Substance Use
    • Mental Health Support for Frontline Staff
    • NIHB New Listing and Dispensing Update
    • WHO Academy App for Healthcare Providers

    • Ask the Customer Experience and Administration Team
    • Easier Process to Order PPE from RONCO Announced
    • Reminder: Call for Resolutions

    • Methadone, Buprenorphine and the Community Complimentary Live Webinar Series

    • Store Risk Prevention Tips

    • DDD Notice No. 20088 Posted May 13, 2020 Notice: Making Changes to the Trillium Drug Program in Response to COVID-19
    • DDD Notice No. 20087 Posted May 13, 2020 Executive Officer Notice: Regulatory Amendments to Ontario Drug Benefit Program Co-payments

    • Importation of Spanish-Labelled Salbutamol Aldo-Union inhalers due to Shortage of Canadian-Labelled Salbutamol
    • Importation of Fresenius Propoven 2% due to Shortage of Canadian Labelled Propofol Injection 1% Products
    • Important Safety Information - Importation of Teva UK-Labelled Salamol CFC-Free (Salbutamol Sulfate) Inhaler due to Shortage

  • News for the Week of May 12, 2020

    This content is only available to Association members. Please log in to access this content.

    Become a member

    or Sign In

    • OCP Consultation on Expanding Scope of Practice: Pharmacist Prescribing for Minor Ailments
    • Updated: COVID-19 Case Definition and Reference Document for Symptoms
    • Managing Stress When Our World Has Come to a Halt: Free Webinar from PharmacyU
    • COVID-19 Drug Evidence Initiative (CDEI)
    • Nursing Week: May 11 - 17, 2020

    • Ask the Practice Support Network
    • New Pricing for Personal Protective Equipment (PPE) From RONCO
    • ICYMI: OPA’s Partnership with Relief Buddy Continues. No Fees Until June 2020!

    • Pandemic Tips: Medication Renewal

    • What to Consider Before Selling or Buying a Pharmacy
    • OPA Store Insurance Renewal 2020 - 2021

    • DDD Notice No. 20086 posted May 6, 2020 Prescription Forgery Alert

    • Important Safety Information for Certain Respirator Masks
    • Unauthorized Test Kits Claiming to Diagnose or Detect COVID-19 Put Your Health at Risk
    • Importation of US-Labelled Ketamine Hydrochloride for Injection due to Potential Shortage of Canadian-Labelled Ketamine
    • Protect yourself and your family from poisonings: always read and follow the label directions when using hand sanitizers, disinfectants, household cleaning products and bleaches

  • News for the Week of May 4, 2020

    This content is only available to Association members. Please log in to access this content.

    Become a member

    or Sign In

    • Pharmcovid19 #PharmacistsOnTheFrontline
    • COVID-19 OPA advocacy web page
    • Updated: COVID-19 pharmacy signage
    • Updated: Return to work guidance tool
    • Mental health resources from Canadian Foundation for Pharmacy and Therappx
    • ICYMI: OPA's position on pandemic pay for publicly-paid pharmacy professionals

    • Ask the Customer Experience and Administration Team
    • OPA’s Partnership with Relief Buddy Continues. No Fees Until June 2020!

    • Pandemic Tips: Opioid Agonist Therapy

    • Get Your Reduced Driving Refund
    • OPA Store Insurance Renewal 2020 - 2021

    • DDD Notice No. 20085 Posted May 5, 2020 Prescription Forgery Alert
    • DDD Notice No. 20084 Posted May 1, 2020 Executive Officer Notice: Proposed Regulatory Amendments to Ontario Drug Benefit (ODB) Program Co-payments and Dispensing Fees
    • DDD Notice No. 20083 Posted May 1, 2020 Proposed Regulatory Amendments related to the Trillium Drug Program Deductible
    • DDD Notice No. 20081 Posted April 29, 2020 Executive Officer Notice: Brand Reference Price Regulations Amendment

    • Axid (Nizatidine) Drug Recalled Due to Presence of NDMA
    • Clinical Trial Looking at the Potential Use of Convalescent Plasma to Treat COVID-19
    • Health Product InfoWatch - April 2020
    • Importation of US-Labelled QUELICIN (Succinylcholine Chloride Injection) and US-Labelled Rocuronium Bromide Injection Due to Shortage of Canadian-Labelled Products and Importation of US-Labelled • • Pancuronium Bromide Injection and US-Labelled Vecuronium Bromide for Injection Due to Shortage of Neuromuscular Blocker Products

  • News for the Week of April 28, 2020

    This content is only available to Association members. Please log in to access this content.

    Become a member

    or Sign In

    • Updated OPA's A Pharmacist's Guide to Pandemic Preparedness
    • Updated COVID-19 Pharmacy Signage
    • COVID-19 and Substance Use
    • Strategies for Managing Shortages of Salbutamol
    • OPA Communications Supporting COVID-19 Initiatives
    • Express Scripts Canada - Update - Electronic Data Interchange (EDI) Direct Reimbursement Claim Reversals
    • Express Scripts Canada - NIHB Pharmacy Spring Newsletter
    • Diabetes Pharmacists Network Offers Savings on Diabetes Resources

    • Ask the Practice Support Network

    • New Pandemic Tips from OPA Course Instructors

    • Personal Professional Liability Insurance (PLI) and Privacy Breach
    • New Changes to OPA's Auto and Home Insurance Program
    • OPA Store Insurance Renewal 2020 - 2021

    • DDD Notice No. 20080 posted April 28, 2020 Prescription Forgery Alert
    • DDD Notice No. 20079 Posted April 28, 2020 Health Network System (HNS) and Narcotics Monitoring System (NMS) Outage Notification to Ontario Drug Programs Agencies
    • DDD Notice No. 20078 Posted April 27, 2020. Executive Officer Notice: Updated Quarterly Report Back Form for the Ontario Naloxone Program for Pharmacies
    • DDD Notice No. 20076 Posted April 22, 2020 ODB Formulary – Edition No. 43, Summary of Changes – April 30, 2020

    • Discontinuation of Sale and Distribution of Coumadin® (Warfarin Sodium) Tablets, for Oral Use

    • Chloroquine and Hydroxychloroquine Can Have Serious Side Effects. These Drugs Should Be Used Only Under the Supervision of a Physician

  • News for the Week of April 21, 2020

    This content is only available to Association members. Please log in to access this content.

    Become a member

    or Sign In

    • OPA Guidance Document on Providing Virtual Care in Pharmacy
    • Updated Pharmacy Tools
    • Third-party Payor Tool on Standard Refill Policies
    • COVID-19 Policy Exceptions
    • Pharmacy Staff Return to Work Guidance
    • Post-Consumer Returns of Controlled Substances and the Patch-for-Patch Fentanyl Return Program
    • COVID-19 Guidance for Naloxone Kit Distribution
    • Pharmacists' Matters - Episode 2: Pharmacy in the Face of Pandemic
    • OPA News Headlines

    • Ask the Customer Experience and Administration Team
    • Dell Canada Special Offer

    • New Pandemic Tips from OPA Course Instructors

    • Did You Know Hospital Coverage is Provided by Your OPA Secure Health Plan?
    • OPA Store Insurance Renewal 2020 - 2021

    • DDD Notice No. 20075 posted April 21, 2020 Prescription Forgery Alert
    • DDD Notice No. 20074 Posted April 17, 2020 Prescription Forgery Alert
    • DDD Notice No. 20073 Posted April 16, 2020 Prescription Forgery Alert
    • DDD Notice No. 20072 Posted April 15, 2020 Executive Officer Notice: Ontario Drug Benefit Program and Exceptional Access Program Changes During the COVID-19 Public Health Emergency

    • Shortage of Salbutamol Inhalers in Canada
    • Clinical Management Support: Known Interference Between Hemlibra® (Emicizumab Injection) and Lab Assays Used to Diagnose Coagulopathy / DIC Caused by COVID-19 Infection - Hoffmann-La Roche Ltd.
    • Health Canada is Temporarily Authorizing the Use of Technical-Grade Ethanol in Hand Sanitizer Products: Always Follow the Label Directions When Using Alcohol-Based Hand Sanitizers

Back to top